DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/34dzt6/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Acucela Inc.
- Amarantus Bioscience Holdings, Inc.
- Applied Genetic Technologies Corporation
- Asklepios BioPharmaceutical, Inc.
- BioDiem Ltd
- Caladrius Biosciences, Inc.
- DNAVEC Corporation
- Dompe Farmaceutici S.p.A.
- Genable Technologies Limited
- GenSight Biologics SA
- Grupo Ferrer Internacional, S.A.
- International Stem Cell Corporation
- Isis Pharmaceuticals, Inc.
- Mimetogen Pharmaceuticals Inc.
- Neurotech Pharmaceuticals, Inc.
- Ocata Therapeutics, Inc.
- Orphagen Pharmaceuticals, Inc.
- QLT Inc.
- R-Tech Ueno, Ltd.
- ReNeuron Group Plc
- Sanofi
- Shire Plc
- Spark Therapeutics, Inc.
- Sun Pharma Advanced Research Company Ltd.
Drug Profiles
- AMRS-001
- Antibodies to Antagonize IL-6 for Retinitis
- BDM-E
- BNP-RP
- CB-11
- ECL-1
- emixustat hydrochloride
- FIB-111
- Gene Therapy for Glaucoma and Retinitis Pigmentosa
- Gene Therapy for Ocular Diseases
- Gene Therapy for Ophthalmology
- Gene Therapy for Retinitis Pigmentosa
- Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa
- Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa
- GS-020
- GT-038
- ISISRHO-2.5Rx
- KIRA-6
- NT-501
- OCU-100
- PRO-015
- proinsulin human SR
- QLT-091001
- Recombinant Human Nerve Growth Factor
- ReN-003
- Retinal Progenitor Cells for Ophthalmological Disorders
- RGX-321
- RST-001
- SAR-421869
- SHP-630
- Small Molecule for Retinitis Pigmentosa
- Small Molecule to Agonize Neurotrophin Receptor for Retinitis Pigmentosa
- Small Molecules for CNS Disorders and Ophthalmology
- Small Molecules for Retinitis Pigmentosa
- Small Molecules for Retinitis Pigmentosa
For more information visit http://www.researchandmarkets.com/research/34dzt6/retinitis
